The committee voted that FDA should restrict use of LYNPARZA plus abi/pred to these BRCAm mCRPC patients
Lebrikizumab is an investigational high-affinity and potent IL-13 inhibitor being studied in adult and adolescent patients
Bayer reported the highest market capitalization growth of 23.1% during Q1 2023
mRNA-4157 (V940) in combination with KEYTRUDA reduced the risk of recurrence or death by 44% compared to KEYTRUDA alone in stage III/IV melanoma patients
Acceptance based on results from the Phase 3 KEYNOTE-859 trial, which showed significant overall survival benefit in these patients with HER2-negative disease, regardless of PD-L1 expression
The data from this study show that MM-II has the potential to provide durable pain relief for our patients
AstraZeneca and Merck are committed to working with the FDA to bring LYNPARZA in combination with abi/pred to patients diagnosed with mCRPC.
First approval for Daiichi Sankyo and AstraZeneca’s ENHERTU in China
Dr. Adams brings more than two decades of experience leading the manufacturing of biologic and gene therapies at all stages of development.
Merck and Ridgeback will appeal the decision and request a re-examination of the CHMP’s opinion.
Subscribe To Our Newsletter & Stay Updated
